Setting the New Standard for Health Economics and Outcomes Research
In the world of health economics and outcomes research (HEOR), the annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference is the Super Bowl of real-world evidence (RWE). Each year, the world’s leading Life Sciences and government research teams present breakthrough studies leveraging RWE to track trends in patient behavior, drug adherence, gaps in care, and more. Ultimately, RWE-powered research helps to inform everything from policy and regulatory decisions to public health and commercial Life Sciences strategies.
That’s why Komodo Health™ is so proud to have been a part of some 17 different studies that were presented at ISPOR 2023. Supporting a variety of use cases and addressing therapeutic areas ranging from COVID-19 to cancer, Komodo’s Healthcare Map™ has played a key role in delivering deeper, more nuanced insights into real-world patient journeys.
Tapping RWE to Understand COVID-19 Treatment Disparities
One such study was conducted by the Reagan-Udall Foundation and was commissioned by the U.S. Food and Drug Administration. This research explored the treatment utilization and key characteristics of COVID-19 patients treated with monoclonal antibody (mAB) therapy in the outpatient setting.
The presentation, “Treatment Utilization and Key Characteristics of COVID-19 Patients Treated with Monoclonal Antibody Therapy in the Outpatient Setting”, focused on identifying key demographic information and medical histories of patients treated with mAb therapies. Specifically, the research set out to identify any meaningful trends in race, ethnicity, and pre-existing medical conditions among patients treated with mAb therapy. It found that the lion’s share of patients receiving the therapy was White (82.6%) and non-Hispanic or Latino (90.8%) and that most patients (78.9%) had at least one pre-existing condition — most commonly heart and mental health conditions.
These findings expose a stark lack of representation among Black and Hispanic or Latino patients in the mAb therapy patient population, which will not come as a surprise to those who have been following disparities in care in COVID-19 treatment. This work is a significant new use case demonstrating how RWE offers new insights to policy and regulatory bodies to better inform decision-making for critical initiatives. RWE Powers Real-World Insights
The presentation is further evidence of the critical role that RWE is playing in the research strategies of the world’s leading organizations and an affirmation that Komodo is leading the way forward in the RWE arena. Komodo’s Healthcare Map sets a new standard, offering the depth, breadth, nuance, and reliability necessary to support crucial decisions in settings ranging from regulatory to business to public health.
Here’s a look at some other examples of Komodo-powered research being presented at ISPOR this year:
- Real-World Economic Burden Pre- and Post-Progression to Metastatic Castration-Resistant Prostate Cancer (mCRPC) and after First-Line mCRPC Therapy Initiation: In this study, Janssen Pharmaceuticals and Duke University analyzed the healthcare costs of patients with advanced prostate cancer who develop resistance to androgen deprivation therapy and progress to mCRPC.
- Economic Burden in Patients with Hemophilia with Inhibitors: Results from a Real-World Cohort Study in the United States: For this study, Novo Nordisk tracked healthcare treatment patterns and outcomes for patients with hemophilia A and B who have inhibitors (HAwI/HBwI), a subtype of hemophilia with limited and expensive treatment options and higher disease burden.
- Depression Severity Among Patients with Psychiatric Disorders During the COVID-19 Pandemic: For this podium presentation, the Komodo Health Clinical Research team analyzed trends in depression severity among patients with psychiatric disorders during the pandemic.
Together, these analyses and dozens more presented at ISPOR offer a fascinating window into the depth and breadth of research being made possible with RWE. Our partners across Life Sciences, advocacy organizations, and governing bodies are using RWE to better understand patient experience and incorporate that data into their decision-making processes. With Komodo’s platform providing access, these insights can be trusted to deliver a nationally representative, highly detailed view of how different segments of the patient population are moving throughout the healthcare system.
Read more about all the studies Komodo powered at ISPOR.